Q-omics provides the consensus-scored IFNA22P profile across patient tissues and cancer cell-line models. IFNA22P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, IFNA22P is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, IFNA22P RNA expression shows 6,569 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight UVM, HNSC, and CCRCC as cancer lineages where IFNA22P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFNA22P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFNA22P survival associations across molecular data types. IFNA22P RNA expression shows survival associations in the most cancer types (15), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFNA22P RNA expression–survival associations across cancer types. High IFNA22P expression shows unfavorable associations in UVM, LUAD, HNSC and COAD, but favorable associations in KIRC and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for IFNA22P RNA expression.
This table summarizes IFNA22P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for IFNA22P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFNA22P shows lower tumor expression in LUSC and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher IFNA22P RNA expression in tumor versus normal tissue (log2 FC = +0.095, t-test p = .042).
This table shows molecular features associated with IFNA22P in patient tissues and cancer cell lines. In patient samples, IFNA22P shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
